ORIGINAL RESEARCH

Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population

Hermann Brenner[1–3]
Hongda Chen[1,4]

[1]Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), [2]Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), [3]German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; [4]Program Office for Cancer Screening in Urban China, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Chaoyang District, Beijing, People's Republic of China

Background: A multitarget stool DNA test (MSDT) that showed higher sensitivity but lower specificity than a fecal immunochemical test (FIT) for hemoglobin in one recent study from the US and Canada, is increasingly used for colorectal cancer (CRC) screening, despite its ~20-fold higher costs compared to FITs. We aimed to assess diagnostic performance of a quantitative FIT in an independent study among participants of screening colonoscopy and to compare it with the previously reported performance of MSDT.

Methods: A total of 3494 participants, aged 50–84 years, who underwent screening colonoscopy in private gastroenterological practices in Germany, and who provided a stool sample before colonoscopy to be evaluated by a commercially available quantitative FIT (FOB Gold®) were included. Diagnostic performance (sensitivity, specificity) for detecting CRC or advanced precancerous lesions (APCLs) was evaluated by comparison of test results with findings at screening colonoscopy. In addition to the original cutoff, we used an adjusted cutoff yielding the same specificity as reported for the MSDT to enhance comparability.

Results: The most advanced finding at colonoscopy was CRC and APCL in 30 (0.86%) and 359 (10.3%) cases, respectively. At a cutoff yielding the same specificity as reported for MSDT (86.6%), the sensitivities (95% CI) of the FIT for detecting CRC and APCL >1 cm were 96.7% (82.8–99.9%) and 54.3% (48.3–60.3%), respectively. These sensitivities are higher than those reported for MSDT (92.3% and 43.6%, *p*=0.66 and 0.003, respectively).

Conclusion: In this large screening population, FIT showed equivalent or better diagnostic performance in comparison to reported performance of MSDT.

Keywords: colorectal cancer screening, fecal occult blood test, fecal immunochemical test, sensitivity, specificity, test performance

Introduction

Several randomized controlled trials have demonstrated that screening by guaiac-based fecal occult blood tests (gFOBTs) is effective in decreasing colorectal cancer (CRC) mortality.[1–3] However, traditional gFOBTs are limited by low sensitivity for detecting CRC and its precursors.[4] Meanwhile, fecal immunochemical tests (FITs) for human hemoglobin have been well established, showing better diagnostic performance than traditional gFOBTs.[5,6] A recent meta-analysis reported a pooled sensitivity (95% CI) and specificity (95% CI) for detecting CRC of 79% (69−86%) and 94% (92−95%), respectively.[6]

In a recent study in a large screening population from the USA and Canada, a multitarget stool DNA test (MSDT) that combines quantitative molecular assays for *KRAS* mutations, aberrant *NDRG4* and *BMP3* methylation, and β-actin with a hemo-

Correspondence: Hermann Brenner
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 581, 69120 Heidelberg, Germany
Tel +49 6221 421301
Fax +49 6221 421302
Email h.brenner@dkfz-heidelberg.de

377

globin immunoassay was compared with a commercial FIT.[7] In this study, which was sponsored by the manufacturer of the MSDT and which employed intentional oversampling of older adults ≥65 years of age, MSDT detected significantly more cancers but had more false-positive results than the FIT (sensitivity 92.3% versus 73.8%, specificity 86.6% versus 94.9%). This MSDT whose costs exceed the costs of FITs ~20-fold[8] and which requires substantially more complex logistics for stool sampling (collection of a whole bowel movement) has been claimed to be the new high bar benchmark for noninvasive CRC screening.[9] The test is commercially available as Cologuard™ and increasingly used for CRC screening after Food and Drug Administration (FDA) approval in August 2014 and start of Medicare coverage in October 2014.

We assessed diagnostic performance of a quantitative FIT in an independent study conducted in the target population and typical age range for CRC screening in Germany and compared the results with the reported performance of MSDT.

Methods
Study design and study population
This analysis was conducted in the context of the German BLITZ study (Begleitende Evaluierung innovativer Testverfahren zur Darmkrebsfrüherkennung), which has been described in detail elsewhere[5,10] and which is registered in the German Clinical Trials Register (DRKS-ID: DRKS00008737). Briefly, participants of screening colonoscopy, which is offered in Germany since 2002, are consecutively recruited in gastroenterology practices in Southern Germany since December 2005. Stool and blood samples are collected from participants prior to colonoscopy. Clinical data are extracted from colonoscopy and histology reports, in a standardized manner, by trained research assistants who, like the endoscopists, are blinded with respect to results of blood or stool tests. Written informed consent is obtained from each participant. The study was approved by the ethics committees of the University of Heidelberg and of the responsible state physicians' boards.

In various periods of recruitment, different FITs were evaluated. For this analysis, we included participants recruited at ages 50–84 years (the age range included in the MSDT study) from November 2008 to September 2014 when the same quantitative FIT (FOB Gold®; Sentinel Diagnostics, Milano, Italy) was applied (n=4203). The following exclusion criteria were applied to ensure the study participants to represent an average risk screening population and to minimize the potential of false-negative findings of screening colonoscopy: 1) history of CRC or inflammatory bowel disease (n=32), 2) colonoscopy in the preceding 5 years (n=193), 3) inadequate bowel preparation before colonoscopy (n=432), and 4) incomplete colonoscopy (cecum not reached, n=52). Finally, 3494 remaining participants were included in the analysis.

Collection of stool samples
Participants were handed out stool collection devices at a pre-colonoscopy practice visit. Before February 2012, participants were asked to fill a small plastic container with a native stool sample, store it in a provided plastic bag, keep it in the freezer and bring it to the practice visit for colonoscopy. At the practice visit, the sample was immediately stored at −15 to −40°C, shipped on dry ice to the study's central laboratory (Labor Limbach, Heidelberg, Germany) and stored again at −70°C until analysis. From February 2012 onward, participants were asked to collect a stool sample according to the manufacturer's instruction in a collection tube containing hemoglobin stabilizing buffer (10 mg stool in 1.7 mL extraction buffer; Sentinel Diagnostics; Ref. 11561H). The tubes were mailed in sealed envelopes to the German Cancer Research Center (Deutsches Krebsforschungszentrum [DKFZ]). At DKFZ, the tubes were kept at 2–8°C in the refrigerator before transfer in a temperature-controlled environment to the central laboratory, where they were stored at 2–8°C in the refrigerator until FIT analysis.

Laboratory analyses
Laboratory personnel were blind with respect to colonoscopy findings. For analyses using frozen stool samples, the stool samples were thawed once for extraction of 10 mg stool, which was then diluted in the extraction buffer (1.7 mL, i.e., dilution: 1:170). All FIT analyses were conducted in fully automated manner using Abbott Architect c8000. Positivity was defined according to the cutoff recommended by the manufacturer (17 µg hb/g feces=100 ng hb/mL buffer).

All collection, arrival and analysis dates of fecal samples were documented. For frozen stool samples, the median time (interquartile range [IQR]) between fecal sampling and laboratory analysis was 6 (IQR=4−12) days; for fresh stool samples, the median time (IQR) between fecal sampling and arrival in DKFZ was 4 (IQR=3−5) days, and the median time between arrival at DKFZ and laboratory analysis was 2 (IQR=1−4) days.

Statistical analyses
As previously reported in detail,[11] FIT results and diagnostic performance indicators were very similar for both

stool-sampling methods, and data were therefore pooled for analysis. We first described the study population according to basic sociodemographic characteristics, overall FIT positivity rate and findings at screening colonoscopy, which was conducted blinded with respect to FIT results in all cases.

We then determined the sensitivity of FOB Gold according to the most advanced finding at screening colonoscopy: 1) CRC (any stage or stages I–III only), 2) advanced precancerous lesions (APCLs) including advanced adenomas (defined by at least one adenoma with any of the following features: ≥1 cm in size, tubulovillous or villous components, high-grade dysplasia) and sessile serrated polyps ≥1 cm, AND 3) non-advanced adenoma. Sensitivities were also derived for combinations of the aforementioned groups, such as participants with CRC or any APCL. Specificity was determined for participants without CRC or APCL.

To facilitate comparisons of diagnostic performance with MSDT, we also calculated sensitivities and specificities after adjustment of the FIT cutoff in such a way that it yielded the same specificity (86.6%) as previously reported for MSDT.[7] This was achieved by lowering the cutoff from the value recommended by the manufacturer, i.e., from 17 µg hb/g feces to 8.5 µg hb/g feces. Furthermore, in order to assess diagnostic performance over a wide range of possible cutoffs, receiver operating characteristic (ROC) analysis using quantitative test results was conducted for the outcomes CRC and any advanced neoplasia (CRC or any APCL), and areas under the curves (AUCs) along with 95% CIs (derived by 2000 bootstrap samples) were calculated.

In addition to analyses in the entire study population, subgroup analyses were performed according to the location of the most advanced neoplasm (proximal of or at the splenic flexure, distal otherwise). To account for a potential role in age differences in our study population and the study population of the MSDT study,[7] we also calculated age-adjusted values of FIT sensitivities and specificity as weighted averages of the age-specific values in age groups <65 and 65+ years, with weights equal to the proportion of study participants in the two age groups in the MSDT study.

Statistical analyses were performed with R statistical software version 3.1.1.[12] Differences in sensitivity and specificity were tested for statistical significance by two-sided chi-square test and, where indicated, Fisher's exact test at α=0.05.

Results

Table 1 shows main characteristics of the BLITZ study population. Corresponding data from the MSDT study are shown for comparison.[7] The BLITZ study included almost equal

Table 1 Recruitment and characteristics of study population in the BLITZ sample evaluating FOB Gold compared to the MSDT study evaluating Cologuard[7]

Recruitment		MSDT study evaluation of Cologuard[7]		BLITZ study evaluation of FOB Gold®	
		June 2011–November 2012, private practices and academic centers in the US and Canada		November 2008–September 2014, private practices in Germany	
Characteristics of study population		n	%	n	%
Sex	Male	4625	46.3	1737	49.7
	Female	5364	53.7	1757	50.3
Age, years	50–54			98	2.8
	55–59	2862	28.7	1514	43.3
	60–64	819	8.2	735	21.0
	65–69	3670	36.7	535	15.3
	70–74	1735	17.4	447	12.8
	75–84	903	9.0	165	4.7
Most advanced finding at screening colonoscopy	CRC	65	0.65	30	0.86
	Stage I	29	0.29	10	0.29
	Stage II	21	0.21	4	0.11
	Stage III	10	0.10	13	0.37
	Stage IV	4	0.04	3	0.09
	APCL#	757	7.58	359	10.27
	≥1 cm	691	6.92	276	7.90
	<1 cm	66	0.66	83	2.37
	Non-advanced adenoma	2893	28.96	688	19.69
	None of the above	6274	62.81	2417	69.18

Note: #APCLs, including advanced adenomas and sessile serrated polyps ≥1 cm.
Abbreviations: MSDT, multitarget stool DNA test; CRC, colorectal cancer; APCL, advanced precancerous lesion.

numbers of men and women. The vast majority (93.2%) of participants were aged between 55 and 74 years, mean age was 62.1 years.

At least one neoplasm was found in 30.8% of participants, the most advanced finding being CRC, APCL and non-advanced adenoma in 0.86%, 10.3% and 19.7% of participants. CRC was most commonly diagnosed in stage I or stage III, only three of 30 cases (10%) had stage IV CRC. A total of 77% of APCLs were ≥1 cm. The MSDT study population had included a slightly higher proportion of women (53.7% versus 50.3%) and a substantially higher proportion of participants ≥65 years (63.1% versus 32.8%).[7] Prevalences of CRC and APCL were somewhat higher in the BLITZ study. Although these differences would affect positive or negative predictive values, they should not hinder comparisons of sensitivity and specificity.

Data on sensitivity and specificity of FOB Gold, using the cutoff recommended by the manufacturer (17 µg hb/g feces), are summarized in Table 2. CRC was detected in 29 of 30 cases, yielding a sensitivity of 96.7%. The single missed CRC was a stage I CRC in a 69-year-old woman. The sensitivities for any APCL, APCL ≥1 cm and non-advanced adenoma were 33.7%, 39.9% and 10.0%, respectively, and 73.3%, 45.4% and 38.6% for the combined end points "CRC or high-grade dysplasia", "CRC or APCL ≥1 cm" or "CRC or any APCL", respectively. With the exception of CRC, sensitivities were somewhat lower, but specificity was significantly higher (92.8% versus 86.6%, p<0.0001) than reported for Cologuard in the MSDT study.[7]

Shifting the cutoff of FOB Gold from 17.0 to 8.4 µg hb/g feces lowered the specificity to the level reported for Cologuard.[7] This shift did not affect the already very high sensitivity for CRC, but increased the sensitivity for any APCL, APCL ≥1 cm and non-advanced adenomas to 47.4%, 54.3% and 19.5%, respectively (Table 2). All these sensitivities are higher (in case of APCL ≥1 cm or the combined end point CRC or APCL ≥1 cm significantly so, p=0.003 and 0.002, respectively) than the sensitivities reported for Cologuard.[7] Age adjustment to the age distribution of the MSDT study[7] increased the sensitivity of FOB Gold for detecting APCL ≥1 cm above the levels observed for Cologuard even without adjustment of the cutoff while maintaining superior specificity (Figure 1), given the substantially higher sensitivity in age group 65+ years compared to age group <65 years (49.6% versus 32.5%).

In order to assess overall test performance of FOB Gold over a wider range of cutoffs, ROC analyses were performed for the detection of CRC or any advanced neoplasm, i.e., CRC

Table 2 Comparison of diagnostic performance of Cologuard in the MSDT study[7] and of FOB Gold in the BLITZ study

Most advanced finding at screening colonoscopy*	Cologuard, MSDT study[7]			FOB Gold, BLITZ study								
				N_total	Original cutoff				Adjusted cutoff			
	N_total	N_pos	Indicator % (95% CI)		N_pos	Indicator % (95% CI)	Difference* % (95% CI)	p-value*	N_pos	Indicator % (95% CI)	Difference* % (95% CI)	p-value*
			Sensitivity			Sensitivity				Sensitivity		
CRC, any stage	65	60	92.3 (83.0 to 97.5)	30	29	96.7 (82.8 to 99.9)	4.4 (−9.7 to 13.9)	0.66	29	96.7 (82.8 to 99.9)	4.4 (−9.7 to 13.9)	0.66
CRC stages I–III	60	56	93.3 (83.8 to 98.2)	27	26	96.3 (81.0 to 99.9)	3.0 (−12.2 to 12.7)	1.00	26	96.3 (81.0 to 99.9)	3.0 (−12.2 to 12.7)	1.00
APCL	757	321	42.4 (38.9 to 46.0)	359	121	33.7 (28.8 to 38.9)	−8.7 (−14.6 to −2.6)	**0.006**	170	47.4 (42.1 to 52.7)	5.0 (−1.3 to 11.2)	0.12
≥1 cm	691	301	43.6 (39.8 to 47.4)	276	110	39.9 (34.0 to 45.9)	−3.7 (−10.4 to 3.2)	0.31	150	54.3 (48.3 to 60.3)	10.8 (3.8 to 17.6)	**0.003**
<1 cm	66	20	30.3 (19.6 to 42.9)	83	11	13.3 (6.8 to 22.5)	−17.1 (−30.3 to −3.8)	**0.01**	20	24.1 (15.4 to 34.7)	−6.2 (−20.5 to 7.9)	0.46
Non-advanced adenoma	2893	498	17.2 (15.9 to 18.6)	688	69	10.0 (7.9 to 12.5)	−7.2 (−9.7 to −4.4)	**<0.001**	134	19.5 (16.6 to 22.6)	2.3 (−0.9 to 5.7)	0.16
CRC or high-grade dysplasia	104	87	83.7 (75.1 to 90.2)	60	44	73.3 (60.3 to 83.9)	−10.3 (−24.0 to 2.3)	0.16	47	78.3 (65.8 to 87.9)	−5.3 (−18.6 to 6.6)	0.41
CRC or APCL ≥1 cm	756	361	47.8 (44.1 to 51.4)	306	139	45.4 (39.8 to 51.2)	−2.3 (−8.9 to 4.3)	0.50	179	58.5 (52.8 to 64.1)	10.8 (4.1 to 17.2)	**0.002**
CRC or any APCL	822	381	46.4 (42.9 to 49.8)	389	150	38.6 (33.7 to 43.6)	−7.8 (−13.6 to −1.8)	**0.01**	199	51.1 (46.1 to 56.2)	4.8 (−1.2 to 10.8)	0.12
			Specificity			Specificity				Specificity		
No CRC or APCL	9167	1231	86.5 (85.9 to 87.2)	3105	225	92.8 (91.8 to 93.6)	6.2 (5.0 to 7.3)	**<0.001**	419	86.5 (85.3 to 87.7)	−0.1 (−1.5 to 1.3)	0.93

Notes: Results for FOB Gold are derived for the original cutoff given by the manufacturer (17 µg hb/g feces) and for an adjusted cutoff (8.4 µg hb/g feces) yielding the same specificity with respect to advanced neoplasms (86.6%) as reported for Cologuard. APCL including advanced adenomas and sessile serrated polyps ≥1 cm. *Differences and p-values refer to comparison with Cologuard.[7] p≤0.05 are in bold.
Abbreviations: MSDT, multitarget stool DNA test; APCL, advanced precancerous lesion; CRC, colorectal cancer; N_pos, number of positive results.

Figure 1 Sensitivity for detecting CRC and APCL ≥1 cm and specificity of FOB Gold (using the original cutoff) compared to Cologuard in the MSDT study (data derived from Imperiale et al),[7] with and without age adjustment of FOB Gold results to age distribution of MSDT study population: FIT-O, FOB Gold using original cutoff, no age adjustment; FIT-A, FOB Gold using original cutoff, age adjusted.
Abbreviations: CRC, colorectal cancer; APCL, advanced precancerous lesion; MSDT, multitarget stool DNA test; FIT, fecal immunochemical test.

or any APCL. AUCs were 0.95 and 0.72 for the two outcomes, respectively. The corresponding AUCs for Cologuard had been reported to be 0.94 and 0.73, respectively.[7]

Table 3 shows sensitivities of FOB Gold by site of neoplasms, again using both the original and the adjusted cutoff. With both cutoffs, sensitivity was substantially higher for distal APCLs than for proximal APCLs. Similar site differences had also been reported for Cologuard.[7] Significantly lower site-specific sensitivities for FOB Gold compared to Cologuard turned to non-significantly higher sensitivities when the cutoff of FOB Gold was adjusted to yield the same specificity as Cologuard.

Discussion

In this large screening population, FOB Gold, a quantitative FIT showed good diagnostic performance not only for detecting CRC (96.7%) but also for detecting APCL, especially large APCL. In particular, 39.9% of APCLs ≥1 cm were detected at a specificity of 92.8%. When the cutoff for positivity was lowered to yield a specificity of 86.6%, the specificity previously reported for MSDT, the sensitivity for detecting APCL >1 cm increased to 54.3%, which is substantially and significantly (p=0.003) higher than the corresponding sensitivity reported for MSDT (43.6%).[7] Our indirect comparison therefore suggests at least equivalent if not superior performance of a single quantitative FIT compared to MSDT.

The specificity of FOB Gold in our study is very close to the pooled estimate of FIT specificity of 94% derived in a recent meta-analysis of 19 studies.[6] However, our estimate of sensitivity for detecting CRC (97%) is substantially higher

Table 3 Comparison of site-specific sensitivity of Cologuard in the MSDT study[7] and of FOB Gold in the BLITZ study

Most advanced finding at screening colonoscopy*	Cologuard, MSDT study[7]			FOB Gold, BLITZ study								
					Original cutoff				Adjusted cutoff			
	N_total	N_pos	Sensitivity % (95% CI)	N_total	N_pos	Sensitivity % (95% CI)	Difference^ % (95% CI)	p-value^	N_pos	Sensitivity % (95% CI)	Difference^ % (95% CI)	p-value^
Proximal CRC	30	27	90.0 (73.4 to 97.9)	5	5	100 (47.8 to 100)	10.0 (−33.9 to 25.6)	1.00	5	100 (47.8–100)	10.0 (−33.9 to 25.6)	1.00
Proximal APCL	431	143	33.2 (28.8 to 37.8)	141	28	19.9 (13.6 to 27.4)	−13.3 (−20.7 to −4.8)	**0.001**	53	37.6 (29.6 to 46.1)	4.4 (−4.4 to 13.7)	0.36
Proximal CRC or APCL	461	170	36.9 (32.5 to 41.5)	146	33	22.6 (16.1 to 30.3)	−14.3 (−21.8 to −5.7)	**0.001**	58	39.7 (31.7 to 48.1)	2.9 (−6.0 to 12.0)	0.56
Distal CRC	35	33	94.3 (80.8 to 99.3)	25	24	96.9 (79.6 to 99.9)	1.7 (−14.4 to 15.0)	1.00	24	96.9 (79.6 to 99.9)	1.7 (−14.4 to 15.0)	1.0
Distal APCL	325	177	54.5 (48.9 to 60.0)	236	104	44.1 (37.6 to 50.7)	−10.4 (−18.6 to −2.0)	**0.017**	132	55.9 (49.3 to 62.4)	1.5 (−6.8 to 9.7)	0.73
Distal CRC or APCL	360	210	58.3 (53.1 to 63.5)	261	128	49.0 (42.8 to 55.3)	−9.3 (−17.1 to −1.4)	**0.023**	156	59.8 (53.5 to 65.8)	1.4 (−6.4 to 9.2)	0.74

Notes: Results for FOB Gold are derived for the original cutoff given by the manufacturer (17 µg hb/g feces) and for an adjusted cutoff (8.4 µg hb/g feces) yielding the same specificity with respect to advanced neoplasms (86.6%) as reported for Cologuard. APCL including advanced adenomas and sessile serrated polyps ≥1 cm; N_pos, number of positive results. *Participants with the respective most advanced finding in both the proximal colon and distal colon or rectum were included in site-specific analyses for both sites. ^Differences and p-values refer to comparison with Cologuard.[7] p≤0.05 are in bold.
Abbreviations: MSDT, multitarget stool DNA test; APCL, advanced precancerous lesion; CRC, colorectal cancer; N_pos, number of positive results.

than the corresponding pooled estimate in the meta-analysis (79%), even though there is a slight overlap of 95% CIs (83–100% and 69–86%, respectively). The meta-analysis had included three cohorts with similarly higher levels of sensitivity between 96% and 100%,[13–15] but the numbers of CRC cases in those studies had been lower (in two of them substantially so: n=6, 14 and 28, respectively) than in our study (n=30).

To our knowledge, no previous study other than the original MSDT study,[7] which had been sponsored by the manufacturer, has reported on the comparison of this test with an FIT in detail. Different FIT cutoffs, resulting in differences in both sensitivity and specificity (with higher cutoffs yielding lower sensitivities and higher specificities and vice versa), often make such comparisons difficult. Adjusting FIT cutoffs to yield the same specificity as MSDT enables an indirect comparison of performance of FIT and MSDT across studies. We have previously reported such an indirect comparison based on a different FIT used in an earlier phase of the BLITZ study.[16] For this FIT (OC Sensor; Eiken Chemicals, Tokyo, Japan), performance had been found to be comparable to performance of MSDT. However, the sample size for this indirect comparison had been much smaller (including 15 CRC cases only), and results were reported in much less detail in letter form only.[16] In the few previous comparative studies of OC Sensor and FOB Gold, diagnostic performance of these FITs was roughly similar,[17–19] even though OC Sensor seemed to show some advantages in terms of analytical performance and test handling.[20]

When the same or even higher diagnostic performance can be achieved by FIT compared with MSDT, other aspects, such as practicality, acceptance and costs, are crucial criteria for test selection. Excellent adherence rates can be achieved in organized FIT-based CRC screening programs,[21–23] and failure rates of FITs due to technical problems seem to be much lower than for MSDT (e.g., 0.3% versus 6.3% in the MSDT study).[7] In light of these results, the ~20-fold higher costs and the need for collection of an entire bowel movement for the MSDT are clear arguments against the use of this test as currently offered for CRC screening. In fact, increased use of this test instead of FIT or other established CRC screening options, such as flexible sigmoidoscopy and colonoscopy, could strongly compromise the otherwise excellent cost-effectiveness of CRC screening consistently demonstrated in multiple studies[24–29] even if longer screening intervals, such as 3- rather than the 1- or 2-year intervals commonly recommended for FIT,[30] should be sufficient for this test. Empirical data supporting prolongation of screening intervals have recently become available for FIT,[31] whereas

we are not aware of such data for the MSDT. Whether this test should be considered the new high bar benchmark for noninvasive CRC screening as previously claimed[9] therefore appears debatable.

Our study has specific strengths and limitations. Strengths include inclusion of a large study population from a true screening setting, with results of screening colonoscopy (the best available albeit not perfect reference test) being available for all study participants. Also, results were worked out and presented in such a way that they allowed the best possible comparison with previously reported results of MSDT. Nevertheless, the most important limitation is that the comparison could only be made in an indirect manner, as MSDT, which is very challenging in terms of sample collection (requiring a whole bowel movement), had not been part of the study protocol and could not be conducted retrospectively using stored stool samples. Therefore, differences in study populations might have confounded comparisons of diagnostic performance. Although both studies were conducted in the same age range (50–84 years) in a true screening setting, the proportion of participants ≥65 years of age was substantially higher (due to intentional oversampling) in the MSDT study than in our study population (63.1% versus 32.8%). As sensitivity was substantially higher among participants ≥65 years of age in our study, this difference led to some underestimation of the advantage in diagnostic performance of FOB Gold in our main analysis. In additional analyses, FOB Gold achieved equivalent sensitivity for detecting CRC or APCL ≥1 cm after adjustment to the age distribution to the MSDT study population even when using the original FIT cutoff that yielded substantially higher specificity.[30] Even though the proportion of stage III CRC was higher and the proportion of stage II CRC was lower in our study than in the MSDT study, this difference should not have affected the comparison, as sensitivity was very high for all CRC stages. However, despite the overall large size of both studies, the low overall numbers of CRC cases (30 and 65, respectively) limit the power of sensitivity comparisons for the CRC end point. Our study also included larger proportions of participants with APCL. Other factors, such as the sex distribution, were roughly similar in both studies.

Therefore, despite its limitations, our study suggests that at least equivalent if not better diagnostic performance for detecting CRC and its precursors can be achieved with a single high-quality quantitative FIT as with MSDT. Given the ~20-fold higher costs of MSDT, its increasing use for CRC screening instead of FIT should be carefully reconsidered as it may compromise the otherwise very high cost-effectiveness of CRC screening.

Acknowledgments

Disclosure

The authors report no conflicts of interest in this work.

References

1. Hewitson P, Glasziou P, Watson E, Towler B, Irwig L. Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (hemoccult): an update. *Am J Gastroenterol*. 2008;103(6): 1541–1549.
2. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. *Gut*. 2012;61(7):1036–1040.
3. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. *N Engl J Med*. 2013;369(12): 1106–1114.
4. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME, Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. *N Engl J Med*. 2004;351(26):2704–2714.
5. Brenner H, Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. *Eur J Cancer*. 2013;49(14):3049–3054.
6. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. *Ann Intern Med*. 2014;160(3):171.
7. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. *N Engl J Med*. 2014;370(14):1287–1297.
8. Lin JS, Piper MA, Perdue LA, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA*. 2016;315(23):2576–2594.
9. Ahlquist DA. Multi-target stool DNA test: a new high bar for noninvasive screening. *Dig Dis Sci*. 2015;60(3):623–633.
10. Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. *Ann Intern Med*. 2009;150(3):162–169.
11. Chen H, Werner S, Brenner H. Fresh vs frozen samples and ambient temperature have little effect on detection of colorectal cancer or adenomas by a fecal immunochemical test in a colorectal cancer screening cohort in Germany. *Clin Gastroenterol Hepatol*. Epub 2016 Oct 26.
12. R-Project [homepage on the Internet]. The R Project for Statistical Computing; Vienna, Austria. Available from: http://www.R-project.org/. Accessed March 31, 2016.
13. Levi Z, Birkenfeld S, Vilkin A, et al. A higher detection rate for colorectal cancer and advanced adenomatous polyp for screening with immunochemical fecal occult blood test than guaiac fecal occult blood test, despite lower compliance rate. A prospective, controlled, feasibility study. *Int J Cancer*. 2011;128(10):2415–2424.
14. Parra-Blanco A, Gimeno-García AZ, Quintero E, et al. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. *J Gastroenterol*. 2010;45(7):703–712.
15. Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. *CMAJ*. 2011;183(13):1474–1481.
16. Brenner H, Werner S, Chen H. Multitarget stool DNA for colorectal-cancer screening. *N Engl J Med*. 2014;371(2):184–185.
17. Rubeca T, Rapi S, Confortini M, et al. Evaluation of diagnostic accuracy of screening by fecal occult blood testing (FOBT). Comparison of FOB Gold and OC Sensor assays in a consecutive prospective screening setting. *Int J Biol Markers*. 2006;21(3):157–161.
18. Faivre J, Dancourt V, Denis B, et al. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer. *Eur J Cancer*. 2012;48(16):2969–2976.
19. Zubero MB, Arana-Arri E, Pijoan JI, et al. Population-based colorectal cancer screening: comparison of two fecal occult blood tests. *Front Pharmacol*. 2014;4:175.
20. Santare D, Kojalo I, Huttunen T, et al. Improving uptake of screening for colorectal cancer: a study on invitation strategies and different test kit use. *Eur J Gastroenterol Hepatol*. 2015;27(5):536–543.
21. Levin TR, Jamieson L, Burley DA, Reyes J, Oehrli M, Caldwell C. Organized colorectal cancer screening in integrated health care systems. *Epidemiol Rev*. 2011;33:101–110.
22. Stegeman I, van Doorn SC, Mundt MW, et al. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening. *Cancer Epidemiol*. 2015;39(3):388–393.
23. Jensen CD, Corley DA, Quinn VP, et al. Fecal immunochemical test program performance over 4 rounds of annual screening: a retrospective cohort study. *Ann Intern Med*. 2016;164(7):456–463.
24. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. *Ann Intern Med*. 2010;153(6):368–377.
25. Lansdorp-Vogelaar I, Knudsen A, Brenner H. Cost-effectiveness of colorectal cancer screening. *Epidemiol Rev*. 2011;33:88–100.
26. Sharp L, Tilson L, Whyte S, et al. Cost-effectiveness of population-based screening for colorectal cancer: a comparison of guaiac-based faecal occult blood testing, faecal immunochemical testing and flexible sigmoidoscopy. *Br J Cancer*. 2012;106(5):805–816.
27. Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. *Clin Gastroenterol Hepatol*. 2013;11(9):1158–1166.
28. Lejeune C, Le Gleut K, Cottet V, et al. The cost-effectiveness of immunochemical tests for colorectal cancer screening. *Dig Liver Dis*. 2014;46(1):76–81.
29. Ladabaum U, Alvarez-Osorio L, Rösch T, Brueggenjuergen B. Cost-effectiveness of colorectal cancer screening in Germany: current endoscopic and fecal testing strategies versus plasma methylated Septin 9 DNA. *Endosc Int Open*. 2014;2(2):E96–E104.
30. US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation. *JAMA*. 2016;315(23):2564–2575.
31. Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MC, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended? *Gut*. 2017;66(7):1262–1267.